Allergan

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
Fierce Pharma
DTC ads
television ads
AbbVie
Humira
Gilead Sciences
Truvada
Allergan
Botox
Flag link:
AbbVie Stays Busy While Working to Complete Allergan Acquisition
AbbVie Stays Busy While Working to Complete Allergan Acquisition
BioSpace
AbbVie
Allergan
M&A
Skyrizi
Reata Pharmaceuticals
Flag link:
FTC requests AbbVie, Allergan for more information on $63 billion deal
FTC requests AbbVie, Allergan for more information on $63 billion deal
Reuters
FTC
M&A
AbbVie
Allergan
Flag link:
AbbVie's premium bid for Allergan isn't enough for one investor, who's suing to block it
AbbVie's premium bid for Allergan isn't enough for one investor, who's suing to block it
Fierce Pharma
AbbVie
Allergan
M&A
Flag link:
Allergan receives FDA approval of Juvéderm VOLUMA XC for mid-face injection
Allergan receives FDA approval of Juvéderm VOLUMA XC for mid-face injection
Pharmaceutical Business Review
Allergan
Juvederm Voluma
FDA
facial aesthetics
Flag link:
Allergan Settles Ahead of Multi-District Opioid Litigation
Allergan Settles Ahead of Multi-District Opioid Litigation
Yahoo/Zacks.com
Allergan
Ohio
opioids
opioid crisis
Flag link:
Are J&J, Endo and Allergan in line for 'global' opioid settlements?
Are J&J, Endo and Allergan in line for 'global' opioid settlements?
Fierce Pharma
Endo International
Allergan
Ohio
opioids
opioid crisis
Flag link:
Breast implant makers vie for customers amid Allergan recall
Breast implant makers vie for customers amid Allergan recall
Mass Device
devices
Allergan
breast implants
FDA
Mentor
Sientra
Flag link:
Not so fast, Endo and Allergan: Ohio's AG is looking past your opioid deals
Not so fast, Endo and Allergan: Ohio's AG is looking past your opioid deals
Fierce Pharma
Ohio
opioids
opioid crisis
Endo International
Allergan
Flag link:
Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study
Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study
Endpoints
Novartis
Amgen
Allergan
biosimilars
Roches
Rituxan
ABP 798
Flag link:
Allergan CEO Saunders lines up for $39M parachute after AbbVie buy
Allergan CEO Saunders lines up for $39M parachute after AbbVie buy
Fierce Pharma
Allergan
executive pay
Pharma CEOs
Brent Saunders
AbbVie
M&A
Flag link:
Table for two: AbbVie was Allergan's only suitor in $63B takeover that shocked the industry
Table for two: AbbVie was Allergan's only suitor in $63B takeover that shocked the industry
Fierce Pharma
AbbVie
Allergan
M&A
Flag link:
Whoops! Allergan's bid to shield Botox manufacturing secrets from competitors backfires
Whoops! Allergan's bid to shield Botox manufacturing secrets from competitors backfires
Fierce Pharma
Allergan
Botox
trade secrets
Flag link:
Allergan says it will shed two drugs as AbbVie takeover looms
Allergan says it will shed two drugs as AbbVie takeover looms
Pharmaforum
Allergan
brazikumab
Zenprep
AbbVie
M&A
Flag link:
AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?
AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?
Fierce Pharma
Allergan
AbbVie
Botox
M&A
Flag link:
Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand
Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand
Yahoo/Reuters
Allergan
earnings
Flag link:
Editas, Allergan launch first in vivo study of CRISPR-based medicine
Editas, Allergan launch first in vivo study of CRISPR-based medicine
BioPharma Dive
Editas Medicine
Allergan
clinical trials
CRISPR
EDIT-101
Flag link:
Among recent megamergers only AbbVie-Allergan looks like a winner: analyst
Among recent megamergers only AbbVie-Allergan looks like a winner: analyst
Fierce Pharma
AbbVie
Allergan
M&A
diversification
Flag link:
Allergan Pulls Textured Breast Implant Following FDA Request
Allergan Pulls Textured Breast Implant Following FDA Request
RAPS.org
Allergan
FDA
product recalls
breast implants
Biocell
Flag link:
AbbVie's Acquisitions Report Card Shows Investors Have a Reason to Worry About the Allergan Buyout
AbbVie's Acquisitions Report Card Shows Investors Have a Reason to Worry About the Allergan Buyout
Motley Fool
Amgen
Allergan
M&A
Flag link:

Pages